07/27/2026
I feel like this information about high dose Wegovy (semaglutide) is everywhere I look right now, but when I sat down to find the original publication of these numbers...there is none. There's "new data," a "new analysis" from a "late-stage trial" that was shared at a conference and on the Novo Nordisk website. But no publication of the data in a peer reviewed journal. And the claim that patients are losing "nearly 28% of their weight" is giving me pause because Eli Lilly's new G3 drug, retatrutide, coming out in 2027 is reported to have a 28% weight loss profile. It's frustrating, because clearly all of this is marketing for the sake of profits and market shares. In my opinion, semaglutide could become the preferred GLP1 medicine if it were significantly less expensive than tirzepatide (Zepbound) or if it were covered by more insurance companies. What do you think?
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.